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Brief reportNormal glutamate but elevated myo-inositol in anterior cingulate cortex inrecovered depressed patientsMatthew J. Taylor a,⁎, Sudhakar Selvaraj a, Ray Norbury a, Peter Jezzard b, Philip J. Cowen aa Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, United Kingdomb The Centre for Functional Magnetic Resonance Imaging of the Brain, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdoma r t i c l e i n f o a b s t r a c tArticle history:Received 12 November 2008Received in revised form 24 February 2009Accepted 24 February 2009Available online 25 March 2009 Background: MRS studies of acutely depressed patients reveal decreased levels of totalglutamate and glutamine (Glx) in frontal cortex which may reﬂect abnormalities of glutamate–glutamine cycling through astrocytes. Frontal Glx levels appear to be normalised after recoveryfrom depression, but it is not known if this composite measure masks ongoing differences inglutamate or glutamine alone.Methods: Medication-free, fully recovered patients with a history of DSM-IV recurrent majordepressive disorder (n=14) and healthy controls (n=16) were scanned at 3T. Short echo timePRESS and PRESS-J spectra were acquired from a 12 cm3 voxel of frontal cortex incorporatingthe anterior cingulate.Results: Levels of Glx and of glutamate alone did not differ between groups. However, myo-inositol concentrations were signiﬁcantly higher in those with a history of depression than incontrols.Limitations: Abnormal MRSmeasureswere not demonstrated during episodes of depression forthese participants, so any evidence of changes with recovery is indirect.Conclusions: The normal glutamatergic measures combined with elevated levels of theastrocytic marker, myo-inositol, suggest that recovery from depression may be associated withchanges in glial function in frontal cortex. © 2009 Elsevier B.V. All rights reserved.Keywords:Magnetic resonance spectroscopyUnipolar disorderGlutamateGlutamineMyo-inositolFrontal cortex1. IntroductionThere is a growing interest in the role of brain glutamatemechanisms in depression (Sanacora et al., 2008), heightenedby the observation that drugs altering glutamate activity suchas the NMDA receptor antagonist, ketamine, and theglutamate release inhibitor, riluzole, may have beneﬁcialeffects in patients with treatment resistant depression(Sanacora et al., 2004; Zarate et al., 2006).Measuring glutamate activity in the brain in humans pres-ents challenges but theuse ofmagnetic resonance spectroscopy(MRS) provides a useful approach. Several studies have appliedprotonMRS to study glutamate levels in depression and overall the evidence suggests that acutely depressed patients havedecreased levels of Glx (a composite measure of glutamate andglutamine) in anterior brain regions (Auer et al., 2000; Hasleret al., 2007; Yildiz-Yesiloglu and Ankerst, 2006). Interestingly alargeMRS studyof occipital cortex reportedanoppositeﬁnding,namely that acutely depressed patients had increased gluta-mate levels (Sanacora et al., 2004), suggesting potentialregional brain differences in Glx regulation in depression.In contrast, there have been few studies of Glx levels inrecovereddepressedpatients but such information is importantin determining the pathophysiological role of glutamate invulnerability to depression. Our group found increased levels ofGlx in occipital cortex in recovered unmedicated depressedpatients (Bhagwagar et al., 2007), consistentwith the increasedconcentrations of glutamate reported in this brain region inacute depression. However, when we examined Glx levels in asubset of these participants in anterior cingulate cortex wefound no difference betweenpatients and controls (BhagwagarJournal of Affective Disorders 119 (2009) 186–189⁎ Corresponding author. University Department of Psychiatry, WarnefordHospital, Oxford OX3 7JX, United Kingdom. Tel.: +44 1865 226466; fax: +441865 251076.E-mail address: matthew.taylor@psych.ox.ac.uk (M.J. Taylor).0165-0327/$ – see front matter © 2009 Elsevier B.V. All rights reserved.doi:10.1016/j.jad.2009.02.022 Contents lists available at ScienceDirectJournal of Affective Disordersj ourna l homepage: www.e lsev ie r.com/ locate / j ad
et al., 2008), again suggesting regional differences in Glx regu-lation in patients with mood disorder. Hasler et al. (2005) alsofound normal Glx levels in anterior cingulate cortex in re-covered depressed participants. The aim of the present studywas to examine Glx levels in anterior cingulate cortex in afurther group of recovered depressed patients. In addition,because levels of glutamate and glutamine can vary indepen-dently of each other we used a further MRS technique, PRESS-J,which permits measurement of glutamate without glutamineat moderate ﬁeld strengths (Hurd et al., 2004).2. Materials and methods2.1. ParticipantsMedication-free, fully recovered patients with a history ofrecurrentmajordepressivedisorder, diagnosedby theStructuredClinical Interview for DSM-IV (n=14; 4M, 10F) and healthycontrols (n=16; 5M,11F) were recruited. All were euthymic forat least three months, and had received no psychotropicmedication within three months (mean=38 months; range8–84 months); three patients were drug naïve. Nine patientshad a family history of mood disorder. Three of the recovereddepressed patients had co-morbid illnesses; one had socialphobia, and two subjects had a history of alcoholmisuse but notdependence. On the day of scanning, mental state ratings wereperformed with the Hamilton Depression Rating Scale, BeckDepression Inventory, and Spielberger State and Trait Anxietyscales. All participants gave written informed consent to thestudy, which was approved by the Oxfordshire Research EthicsCommittee, UK.2.2. MRS methodologyScanningwas performed on a 3T Varian INOVA systemwitha head optimised gradient coil (Tesla Engineering, Storrington,UK) and a head-only transmit/receive quadrature birdcage RFcoil. Datawere acquired from a 30×20×20mmvoxel placed inmedial prefrontal and anterior cingulate cortex anterior to thegenu of the corpus callosum. The voxel was positionedmanually by reference to an axial T1-weighted gradient-echoimagewith the base of the voxel on a plane running through thegenu and splenium of the corpus callosum.PRESS data with water suppression (TE 26 ms, TR 3 s, 64averages), and without (TE 26 ms, TR 3 s) were acquired.PRESS-J data (Hurd et al., 2004) with and without watersuppression were similarly acquired with TE arrayed from35ms to 185ms in 10ms increments (water-suppressed data,total acquisitions=128; non-water suppressed data, totalacquisitions=16; TR=3 s). T1-weighted structural images ofwhole brain were acquired with 2 mm3 voxel resolution.PRESS data were analysed with LCModel software (Pro-vencher, 1993), using the non-water suppressed data for eddycurrent correction, calculating metabolite concentrations rela-tive to creatine in conventional fashion using metabolite basisspectra (alanine, aspartate, creatine, GABA, glucose, glutamine,glutamate, glycerophosphocholine, phosphocholine, lactate,myo-inositol, N-acetylaspartate, N-acetylaspartylglutamate,scyllo-inositol, taurine) and simulated lipid andmacromoleculecomponents. PRESS-J spectrawere zero-order phased, apodisedwith a 5 Hz Gaussian ﬁlter, and summed (Hurd et al., 2004) before analysis. Glutamate levels relative to creatine weremeasured using AMARES (Advanced method for accurate,robust and efﬁcient spectral ﬁtting) (Vanhamme et al., 1997)since metabolite basis spectra were not available for PRESS-Jacquisitions, and the spectral simpliﬁcation and ﬂat baselinesobtained with this technique in vivo make direct single peakﬁtting reliable (Hurd et al., 2004). Concentrations in protonMRS studies are conventionally expressed relative to creatinewhichacts as an internal reference standard in the voxel (see forexample, Sanacora et al., 2004; Hasler et al., 2005); levelsrelative to tissue water were also calculated but not includedhere for reasons of space.FSL FAST (Zhang et al., 2001) was employed to segmentthe structural brain images into grey matter, white matter,and CSF, to allow estimation of voxel composition.2.3. Statistical analysisStatistical analyses were performed in SPSS version 15. Toguard against type I error, the available MRS measures (Glx,glutamate, myo-inositol, choline, and N-acetylaspartate)were initially compared between groups by multivariateanalysis using Wilks' lambda. Two-tailed univariate analysisfor each measure independently was then performed toidentify the basis of any overall group effect. The sensitivity ofeffects to the inclusion or exclusion of covariates (age andvoxel composition) was tested. Group demographics andclinical characteristics were compared by t-test. Powercalculations indicated that a sample size of 30 would have80% power to detect a 10% difference in Glx/Cr betweengroups at 0.05 signiﬁcance level. This is the size of differencetypically seen in studies of depressed patients (Auer et al.,2000; Hasler et al., 2007; Yildiz-Yesiloglu and Ankerst, 2006).3. ResultsParticipants with previous episodes ofmajor depression didnot differ signiﬁcantly from controls in age, or on ratings ofcurrent symptoms of depressionor anxiety (Table 1). TherewasTable 1Group characteristics. Recovered depression(n=14) Controls(n=16)Age (mean and range) 32.6 (18–57) 31.8 (19–63)Gender 4M, 10F 5M, 11FSmoking history 5 smokers 3 smokersBeck Depression Inventory 2.7 (3.1) 1.4 (1.5)Hamilton Depression Rating Scale 0.3 (0.5) 0.1 (0.5)Spielberger Trait Anxiety 36.2 (9.7) 30.1 (5.3) ⁎Spielberger State Anxiety 31.5 (8.7) 30.9 (6.2)Age of onset 22 (10.8)Number of episodes 2.6 (1.2)Lifetime melancholic depression 3Lifetime history of suicide attempts 6Months since last antidepressanttreatment (mean and range) 38 (8–84)Glx/creatine 1.61 (0.15) 1.69 (0.21)Myo-inositol/creatine 0.86 (0.07) 0.78 (0.09) ⁎N-acetylaspartate/creatine 1.08 (0.09) 1.11 (0.15)Choline/creatine 0.31 (0.04) 0.29 (0.02)Glutamate/creatine 1.58 (0.23) 1.66 (0.16)Mean values with standard deviation unless otherwise stated.⁎ pb0.05 t-test. 187M.J. Taylor et al. / Journal of Affective Disorders 119 (2009) 186–189
a higher level of trait anxiety reported in those with previousdepressive illness (36.2±2.6 vs 30.1±1.3, p=0.04).The voxels measured contained predominantly grey matter(69%). Multivariate analysis of MRS results revealed a sig-niﬁcant difference between the groups (Wilks' lambda=0.624,F(5,24)=2.894, p=0.035). However this difference was notexplained by glutamatergic abnormalities, since levels of Glxand glutamate did not differ between groups (pN0.2 in bothcases; Fig. 1, Table 1). Interestingly, myo-inositol levels weresigniﬁcantly elevated in those with a history of major depres-sive disorder (F(1,28)=7.49, pb0.02; Fig.1, Table 1). The eleva-tion of myo-inositol was robust to inclusion of age and voxelcomposition as covariates (F(1,24)=7.611, pb0.02). The groupsdid not differ on other MRS measures (NAA, choline, creatine),nor in voxel composition (pN0.1 in each case, Table 1). Allﬁndings were robust to the inclusion of voxel grey and whitematter composition as covariates.4. DiscussionOur ﬁndings suggest that both Glx (glutamate and gluta-mine) and glutamate alone as measured by proton MRS at 3T are normal in the anterior cingulate cortex of recovereddepressed patients withdrawn from medication. Therefore,based on the results of studies in acutely depressed patients,weconclude that the low Glx concentration in anterior brainregions detected by MRS is likely to be a state marker of acutedepression. This contrasts with ﬁndings in occipital cortex,where levels are apparently elevated in both acutely ill andrecovereddepressedpatients (Bhagwagaret al., 2007; Sanacoraet al., 2004).In some contexts, Glx estimates include a small compo-nent (b10%) attributable to GABA (Sanacora et al., 2008).Reports conﬂict as to whether reduced levels of GABA arefound in the anterior cortex of recovered depressed patients(Bhagwagar et al., 2008; Hasler et al., 2005). In the absence ofspeciﬁc GABA measurements, the data reported here cannotclarify this point since, at most, the reduction in GABA wouldbe reﬂected by a 1% difference in Glx levels which is beyondthe statistical power of this study.The conclusion that glutamatergic abnormalities in anteriorbrain regions are markers of the acute depressive state shouldbe treated as tentative until further studies can be performed.For example, the current group of recovered depressed patientsFig. 1. Individual estimates (points) and group means (bars) for levels of glutamate and glutamine (Glx), glutamate, and myo-inositol in healthy controls (n=16)and medication-free patients recovered from depression (n=14). Levels expressed relative to creatine. (⁎, F(1,28)=7.49, pb0.02).188 M.J. Taylor et al. / Journal of Affective Disorders 119 (2009) 186–189
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